- Home
- / Corestem
Corestem
Revenue
₩28.8 B
FY, 2024
Corestem Summary
Company Summary
- Overview
- Corestem (코아스템) is a biopharmaceutical company that researches and commercializes stem cell technology. It provides NEURONATA-R, a stem cell therapy for amyotrophic lateral sclerosis. In addition, the company focuses on lupus, multiple system atrophy, and osteoarthritis.
- Type
- Public
- Status
- Active
- Founded
- 2003
- HQ
- Seongnam-si, KR | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
LocationsView all
1 location detected
Seongnam-si, Gyeonggi-do HQ
Korea (Republic of)
Pangyo-ro, Bundang-gu
Corestem Financials
Summary Financials
- Revenue (Q3, 2025)
- ₩3.6B
- Gross profit (Q3, 2025)
- (₩1.1B)
- Net income (Q3, 2025)
- (₩7.2B)
- Cash (Q3, 2025)
- ₩536.1M
- EBIT (Q3, 2025)
- (₩7.6B)
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026